Loading
A phase 2 trial of Ipatasertib, Cobimetinib, Trastuzumab emtansine in ovarian cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors is a phase 2 interventional study registered as NCT04931342 by Hoffmann-La Roche, with 176 participants enrolled, started 2021-10-07 and due to reach its primary completion in 2028-02-28. Interventions recorded: Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipatasertib, Roche / Genentech.
Shares Atezolizumab, Roche / Genentech, Bevacizumab.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Paclitaxel / nab-paclitaxel.
Shares Roche / Genentech, Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Atezolizumab, Roche / Genentech, Bevacizumab.
Shares Trastuzumab emtansine, Roche / Genentech, Paclitaxel / nab-paclitaxel.
Shares Trastuzumab emtansine, Roche / Genentech, Paclitaxel / nab-paclitaxel.
Shares Ipatasertib, Trastuzumab emtansine, Atezolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/